Analysis of Clinical Factors and Mortality in Diffuse Large B-cell Lymphoma Patients Over or Under 80 Years of Age

The prognosis of diffuse large B-cell lymphoma (DLBCL) is remarkably improved after R-CHOP therapy. However, there are few detailed reports regarding very elderly DLBCL patients. We investigated relationships between prognostic factors and mortality risk in DLBCL patients, especially those aged 80 y...

Full description

Saved in:
Bibliographic Details
Published in:International journal of gerontology 2018-06, Vol.12 (2), p.100-104
Main Authors: Hasebe, Shinji, Tanaka, Keiko, Miyake, Yoshihiro, Asai, Hiroaki, Takeuchi, Kazuto, Fujii, Tomomi, Kawazoe, Hitoshi, Tanimoto, Kazushi, Yamanouchi, Jun, Azuma, Taichi, Yasukawa, Masaki, Yakushijin, Yoshihiro
Format: Article
Language:English
Subjects:
Diffuse large B-cell lymphoma
Mortality
Prognostic factors
Rituximab clearance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prognosis of diffuse large B-cell lymphoma (DLBCL) is remarkably improved after R-CHOP therapy. However, there are few detailed reports regarding very elderly DLBCL patients. We investigated relationships between prognostic factors and mortality risk in DLBCL patients, especially those aged 80 years or more. The study subjects consisted of 141 patients newly-diagnosed with de novo DLBCL. Information regarding age, sex, stage, performance status (PS), lactate dehydrogenase (LDH), extranodal (EN) involvement, and therapies was available. For the 141 patients, the female sex was significantly inversely related to mortality, whereas age ≥80 years, PS ≥2, and non-standard therapy were significantly positively associated with death. No associations were observed between death and stage, LDH, or EN. When classifying patients by age (
ISSN:1873-9598
DOI:10.1016/j.ijge.2017.11.001